IN2009KN04098A - - Google Patents

Download PDF

Info

Publication number
IN2009KN04098A
IN2009KN04098A IN4098KON2009A IN2009KN04098A IN 2009KN04098 A IN2009KN04098 A IN 2009KN04098A IN 4098KON2009 A IN4098KON2009 A IN 4098KON2009A IN 2009KN04098 A IN2009KN04098 A IN 2009KN04098A
Authority
IN
India
Prior art keywords
component
lyophilised
lyophilised meningococcal
reconstitute
reconstituted
Prior art date
Application number
Inventor
Mario Contorni
Paolo Costantino
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IN2009KN04098A publication Critical patent/IN2009KN04098A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

A liquid Hib component is used to reconstitute a lyophilised meningococcal component, thereby producing a combined meningitis vaccine. A lyophilised meningococcal component can also be reconstituted with an oil-in-water emulsion.
IN4098KON2009 2007-06-04 2008-06-04 IN2009KN04098A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93323507P 2007-06-04 2007-06-04
PCT/IB2008/002121 WO2008149238A2 (en) 2007-06-04 2008-06-04 Formulation of meningitis vaccines

Publications (1)

Publication Number Publication Date
IN2009KN04098A true IN2009KN04098A (en) 2015-08-28

Family

ID=40094241

Family Applications (1)

Application Number Title Priority Date Filing Date
IN4098KON2009 IN2009KN04098A (en) 2007-06-04 2008-06-04

Country Status (13)

Country Link
US (1) US20100203137A1 (en)
EP (1) EP2152302B1 (en)
JP (1) JP5637848B2 (en)
CN (1) CN101678094B (en)
AU (2) AU2008259423A1 (en)
BR (1) BRPI0811979A2 (en)
CA (1) CA2688268A1 (en)
ES (1) ES2555786T3 (en)
IN (1) IN2009KN04098A (en)
MX (1) MX2009013112A (en)
NZ (1) NZ581367A (en)
RU (1) RU2009149359A (en)
WO (1) WO2008149238A2 (en)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ532665A (en) 1998-05-01 2005-11-25 Inst Genomic Research Neisseria meningitidis antigens and compositions
CA2373236C (en) 1999-05-19 2014-08-26 Chiron S.P.A. Combination neisserial compositions
EP2975127A1 (en) 1999-10-29 2016-01-20 GlaxoSmithKline Biologicals SA Neisserial antigenic peptides
WO2001064920A2 (en) 2000-02-28 2001-09-07 Chiron Spa Hybrid expression of neisserial proteins
AU8189501A (en) * 2000-06-29 2002-01-08 Smithkline Beecham Biolog Vaccine composition
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
MX339524B (en) 2001-10-11 2016-05-30 Wyeth Corp Novel immunogenic compositions for the prevention and treatment of meningococcal disease.
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
GB0408977D0 (en) 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
US8431136B2 (en) * 2005-06-27 2013-04-30 Glaxosmithkline Biologicals S.A. Immunogenic composition
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
ES2383231T3 (en) * 2007-10-19 2012-06-19 Novartis Ag Formulations for meningococcal vaccines
ES2532946T3 (en) 2008-02-21 2015-04-06 Novartis Ag Meningococcal PUfH polypeptides
CA2728344A1 (en) * 2008-06-16 2010-01-14 Academia Sinica Compositions for inducing immune responses specific to globo h and ssea3 and uses thereof in cancer treatment
GB0822634D0 (en) 2008-12-11 2009-01-21 Novartis Ag Meningitis vaccines
CN104548082A (en) * 2009-03-24 2015-04-29 诺华股份有限公司 Adjuvanting meningococcal factor H binding protein
BRPI1009829A2 (en) * 2009-03-24 2016-11-16 Novartis Ag meningococcal h-factor binding protein combinations and pneumococcal saccharide conjugates
CN101590225B (en) * 2009-06-19 2012-02-15 长春长生生物科技股份有限公司 Vaccine combining DTP (diphtheria,tetanus and pertussis) and A plus C group meningococcus-b type haemophilus influenzae
CA2803239A1 (en) 2010-06-25 2011-12-29 Novartis Ag Combinations of meningococcal factor h binding proteins
WO2012025873A2 (en) 2010-08-23 2012-03-01 Wyeth Llc STABLE FORMULATIONS OF NEISSERIA MENINGITIDIS rLP2086 ANTIGENS
PE20140173A1 (en) 2010-09-10 2014-02-20 Wyeth Llc NON-LIPIDED VARIANTS OF NEISSERIA MENINGITIDIS ANTIGENS ORF2086
WO2012078482A1 (en) * 2010-12-10 2012-06-14 Merck Sharp & Dohme Corp. Novel formulations which mitigate agitation-induced aggregation of immunogenic compositions
US9283270B2 (en) * 2012-01-20 2016-03-15 Serum Institute Of India Ltd. Method for stabilization of biological molecules
RU2014140521A (en) * 2012-03-08 2016-04-27 Новартис Аг ADJUVANT COMPOSITIONS OF BOOSTER VACCINES
SA115360586B1 (en) 2012-03-09 2017-04-12 فايزر انك Neisseria meningitidis compositions and methods thereof
SG10201602558UA (en) 2012-03-09 2016-05-30 Pfizer Neisseria meningitidis compositions and methods thereof
CA2876138C (en) 2012-06-14 2023-09-19 Novartis Ag Vaccines for serogroup x meningococcus
EP2964665B1 (en) 2013-03-08 2018-08-01 Pfizer Inc Immunogenic fusion polypeptides
CA2923129C (en) 2013-09-08 2020-06-09 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
BR112017017460A2 (en) 2015-02-19 2018-04-10 Pfizer Inc. neisseria meningitidis compositions and methods thereof
SG11201901394XA (en) 2016-09-02 2019-03-28 Sanofi Pasteur Inc Neisseria meningitidis vaccine
AU2018215585B2 (en) 2017-01-31 2022-03-17 Pfizer Inc. Neisseria meningitidis compositions and methods thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5153312A (en) 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
DE69331495T2 (en) 1992-08-31 2002-10-31 Baxter Healthcare Sa VACCINE AGAINST NEISSERIA MENINGITIDIS GROUP C
US5425946A (en) 1992-08-31 1995-06-20 North American Vaccine, Inc. Vaccines against group C Neisseria meningitidis
GB9422096D0 (en) * 1994-11-02 1994-12-21 Biocine Spa Combined meningitis vaccine
SI1082965T1 (en) 1995-06-23 2009-08-31 Glaxosmithkline Biolog Sa A vaccine composition comprising a polysaccharide conjugate antigen adsorbed onto aluminium phosphate
US6299881B1 (en) 1997-03-24 2001-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
AU8189501A (en) 2000-06-29 2002-01-08 Smithkline Beecham Biolog Vaccine composition
PT2332581E (en) 2001-01-23 2015-10-16 Sanofi Pasteur Inc Tri- or tetravalent meningococcal polysaccharide-crm197 conjugate vaccine
GB0115176D0 (en) * 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
DE60325565D1 (en) 2002-03-26 2009-02-12 Novartis Vaccines & Diagnostic MODIFIED SACCHARIDES WITH IMPROVED STABILITY IN WATER
JP4827726B2 (en) * 2003-01-30 2011-11-30 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル Injectable vaccine against multiple meningococcal serogroups
CN103357002A (en) 2003-10-02 2013-10-23 诺华疫苗和诊断有限公司 Liquid vaccines for multiple meningococcal serogroups
GB0405787D0 (en) * 2004-03-15 2004-04-21 Chiron Srl Low dose vaccines
GB0500787D0 (en) * 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
GB0409745D0 (en) * 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
GB0505518D0 (en) * 2005-03-17 2005-04-27 Chiron Srl Combination vaccines with whole cell pertussis antigen
CN1709505B (en) * 2005-07-13 2010-06-16 北京绿竹生物制药有限公司 Polyvalent bacteria capsule polysaccharide-protein conjugate combined vaccine
RU2457858C2 (en) * 2005-09-01 2012-08-10 Новартис Вэксинес Энд Дайэгностикс Гмбх Унд Ко Кг Multiple vaccination including serogroup c meningococci
GB0524066D0 (en) * 2005-11-25 2006-01-04 Chiron Srl 741 ii
ES2383231T3 (en) * 2007-10-19 2012-06-19 Novartis Ag Formulations for meningococcal vaccines

Also Published As

Publication number Publication date
EP2152302B1 (en) 2015-10-07
WO2008149238A2 (en) 2008-12-11
CA2688268A1 (en) 2008-12-11
MX2009013112A (en) 2010-03-01
EP2152302A2 (en) 2010-02-17
JP2010529103A (en) 2010-08-26
CN101678094B (en) 2014-08-27
US20100203137A1 (en) 2010-08-12
AU2008259423A1 (en) 2008-12-11
RU2009149359A (en) 2011-07-20
AU2014204425A1 (en) 2014-08-07
BRPI0811979A2 (en) 2014-10-21
ES2555786T3 (en) 2016-01-08
NZ581367A (en) 2012-05-25
JP5637848B2 (en) 2014-12-10
CN101678094A (en) 2010-03-24
AU2014204425B2 (en) 2015-10-29
WO2008149238A3 (en) 2009-08-06

Similar Documents

Publication Publication Date Title
IN2009KN04098A (en)
MX350285B (en) Methods and compositions for producing hydrocarbons.
WO2014058954A3 (en) Surgical staple insertion device
IN2012DE00840A (en)
WO2010067201A3 (en) MIXING LYOPHILISED MENINGOCOCCAL VACCINES WITH D-T-Pa VACCINES
MX2009011191A (en) Ergonomic syringe.
MX347825B (en) Fastener system with stable engagement and stick fit.
MX2014003463A (en) Adjustable fracturing head and manifold system.
WO2011062987A3 (en) Methods and compositions for producing hydrocarbons
WO2014035146A3 (en) Homomorphic encryption method and decryption method using ring isomorphism, and device using same
GB201211058D0 (en) Fuel system
MX2010001842A (en) Systems and methods for computing a variogram model.
WO2011109481A3 (en) Decorative element for medical devices
WO2013106798A3 (en) Method and apparatus for generating a privilege-based key
BR112013020783A2 (en) screen, method for expanding a screen and method for conforming a screen to a wellbore
WO2011162959A3 (en) Generating recommendations for improving a presentation document
WO2014000106A8 (en) User-selectable ieee 1588 clock class and quality level mapping
WO2013096127A3 (en) Plug and abandonment system
CA2865777A1 (en) 2,2',6,6'-tetraisopropyl-4,4'-biphenol lipid microsphere preparations and preparation methods therefor
JP2015102367A5 (en)
WO2012010862A3 (en) Improved combustible composition
MX2010013103A (en) Thermodynamic cycle with power unit and venturi and a method of producing a useful effect therewith.
UA35566U (en) Technique for inserting first trocar into peritoneal cavity in laparoscopic cholecystectomy
WO2006132966A3 (en) Webbed hiv envelope immunogens, methods for production and use of same
Neakrase Terrestrial Analogs for Venusian Dunes: Sub-Aqueous, Seafloor Dune Fields